UiO:Life Science and the SPARK Norway partners organize monthly open meetings – SPARK Norway Educational Forum
Repurposing of drugs can potentially bring medications with known safety profiles to new patient groups. What is the industry looking for when they consider to invest in a repurposing project? What is the regulatory framework in this area? How is IP handled?
The meeting is part of the SPARK Norway Educational Forum Series 3: Therapeutics and diagnostics.
A part of Nordic Life Science Awards that features exciting academic projects from five Nordic countries illustrating the rich and broad research milieus and their motivation to advance their ideas into innovations for patients.
Clinical trials are essential to develop new treatments. What are the fundamental issues that must be considered when designing clinical trials? What are the pitfalls? What are the dos and don’ts?
Patent strategy is an important part of the innovation process. On this seminar you will hear from experts from Inven2 and learn how you can build a solid patent strategy.
Solid research is the basis for all new innovations. However, too often data generated in academia turns out to be irreproducible by others and therefor fail in translation to new products and treatments. What does it take to achieve reproducible high quality data?
Time and again, a product is being developed, approved, and launched, only to flop in the marketplace. So how can you get your ducks in a row to prepare for a successful product, and how early should you start this process? The answer: begin with the end in mind by creating and using a Target Product Profile (TPP).
National law and European directives, regulations and guidelines regulate development of medicinal product and medical devices. A product's successful journey from research to market and eventually patients requires a well-designed regulatory strategy and several consultations with regulatory authorities.
What are the most important skills you need to have as an entrepreneur and why is your business model just as important as your product?
Funding and partnering is critical when you want to commercialize an academic idea. What are the pitfalls? What is critical? What are the dos and don'ts?
Thomas Hanke EVP, Head of Academic Partnerships at Evotec AG will share his insights on successful models for academia–industry collaboration and lessons learned from evaluating and advancing early stage academic innovations into successful industry projects. He will also introduce Evotec’s BRIDGE concept.
Lecture by Professor Jerome S. Engel "Innovation in the Digital Age: How does it impact health care and the life sciences?"
How can UiO:Life Science´s innovation programme SPARK Norway contribute to turning great ideas from basic research into products?
This Academic Catwalk features exciting academic projects from three Nordic countries illustrating the rich and broad research milieus and their motivation to advance their ideas into innovations for patients.
Akademia og industri er gjensidig avhengig av hverandre for at ideer med utspring i grunnforskning skal tas videre til produkt. Gjennom innovasjonsprogrammet SPARK Norway som er etablert ved UiO, tar vi ut det beste fra begge sider for å bidra til økt verdiskaping innen livsvitenskap. Hvilke gap fyller SPARK-programmet? Og er dette modell som bør spres til hele Norge?
This meeting is cancelled. Please check our web page for meetings relevant for the SPARK Norway community later.
From research to the regulated world – a SPARK Norway educational lecture.
Seminar with GSK: Industry collaboration with academia
Pitching competition where all SPARK Norway teams are invited.
As the third country in Europe, Norway has established the innovation programme SPARK based on Stanford SPARK. At this kick-off UiO showcased the first Norwegian SPARK teams – SPARKees. See pictures and watch videos from the event.
Heiner Dreismann (former CEO of Roche Molecular Systems) on how to successfully build an international life science industry.